Better Health,
Brighter Future
Takeda is committed to the hypoparathyroidism community and continues to work with the FDA on both short- and long-term solutions to bring NATPARA back to patients, which remains our highest priority. We will continue to work diligently on this issue and keep patients and healthcare providers informed of our progress.
If you are a patient with questions about the U.S. recall of NATPARA, please reach out to our OnePath patient services team at 866-888-0660. Healthcare providers with questions should call 800-828-2088.
All of Takeda’s public communications regarding the recall and subsequent actions can be found here:
February 8
December 23
December 18
November 17
October 20
January 21
November 22
October 9
October 9
Takeda’s Letter to Patients about the US Class I Recall of NATPARA >
The above letter has been sent to all NATPARA patients. However, all patients participating in the Special Use Program will receive a separate letter addressing their own individual circumstances. This Recall does not apply to single-use cartridges provided to participants in the NATPARA Special Use Program.
September 26
September 25
September 24
September 24
September 16
September 13
September 6
September 5